Abstract. Lymphatic metastasis of human malignant adenocarcinomas is a critical determinant of prognosis. Lymphangiogenesis, the growth of lymphatic vessels, is closely involved in lymphatic metastasis. However, the mechanisms of tumor lymphangiogenesis are not clearly understood. In a previous study, we showed that human gastric cancer MKN45 cells organize neighboring lymphatic vessels via recruitment of bone marrow-derived lymphatic endothelial progenitor cells in a nude mouse xenograft model. The present results also indicated that human colorectal cancer LS174T and breast cancer SK-BR-3 cells promoted lymphangiogenesis as well as the recruitment of lymphatic endothelial progenitor cells from bone marrow. Among growth factors, which are reported to be involved in lymphangiogenesis, only vascular endothelial growth factor (VEGF)-A was extensively secreted by these three types of adenocarcinoma cells in culture. The well-characterized lymphangiogenic factors VEGF-C and VEGF-D in the culture medium of these three types of adenocarcinoma cells were below the detectable levels in ELISA assay. Secretion of epidermal growth factor (EGF) and hepatocyte growth factor (HGF) was not detected. In vitro culture assay, VEGF-A directly induced the differentiation of bone marrow mononuclear cells into LYVE-1-positive lymphatic endothelial lineage cells. These data collectively suggest the possibility that VEGF-A-rich human adenocarcinomas induce tumor lymphangiogenesis via recruitment of lymphangiogenic endothelial progenitor cells from bone marrow.

Introduction

The presence of lymphatic metastasis to regional lymph node is particularly important for cancer prognosis in common human cancers, including gastric, colon and breast adenocarcinomas (1). Thus, the lymphatic vascular system correlates closely with tumor metastasis (2,3). The recent identification of lymphatic endothelial specific markers, such as hyaluronic acid receptor-1 (LYVE-1) (4) and podoplanin (5), has greatly increased attention on how lymphangiogenesis, the growth of lymphatic vessels, is regulated in the tumor microenvironment. Tumor-induced lymphangiogenesis is mediated by lymphangiogenic growth factors (2,3). The involvement of vascular endothelial growth factor (VEGF)-C and VEGF-D in cancer progression and in tumor-associated lymphatic vessel growth has been demonstrated in several experimental systems (6-8). A role for VEGF-A in tumor-mediated lymphangiogenesis has also been reported (9,10). We have developed a tumor xenograft experimental model using chimeric nude mice with green fluorescent protein (GFP)-positive bone marrow cells (11). In this xenograft model, we showed that human gastric cancer MKN45 cells induced tumor lymphangiogenesis via recruitment of lymphatic endothelial progenitor cells from bone marrow. In the present study, using the same xenograft model, human colorectal cancer LS174 and human breast cancer SK-BR-3 cells also promoted lymphangiogenesis and the recruitment of lymphatic endothelial progenitor cells from bone marrow. These three human adenocarcinoma (gastric cancer MKN45, colorectal cancer LS174 and breast cancer SK-BR-3) cells predominantly produced VEGF-A with negligible secretion of VEGF-C and VEGF-D. VEGF-A, as well as well-known lymphangiogenic factors, VEGF-C and VEGF-D (2,3), induced the expression of LYVE-1, a specific lymphatic endothelial marker, in bone marrow mononuclear cells in culture. The present study shows the role of VEGF-A,
produced by adenocarcinomas, in the tumor lymphangiogenesis via recruitment of lymphatic progenitor cells from bone marrow.

Materials and methods

Materials. L5174T colorectal cancer (12) and SK-BR-3 breast cancer cells (13) were obtained from American Type Culture Collection (ATCC) (Manassas, VA, USA). MKN45 gastric cancer cells (14) were from RIKEN BioResource Center (Tsukuba, Japan). C57BL/6J and C57BL/6-Tg-CAG-EGFP mice were from SLC (Shizuoka, Japan). CanN.Cg-Foxn1nu/CrlCrlj nude mice were from Charles River Laboratories (Yokohama, Japan). ELISA kits and recombinant human VEGFs were from R&D Systems (Minneapolis, MN, USA). Antibody against mouse LYVE-1 was from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Anti-mouse CD34 antibody was from Hycult Biotech (Uden, The Netherlands). Alexa Fluor 594-conjugated anti-rabbit secondary antibody, SuperScript VILO cDNA Synthesis kit and 4',6-diamidino-2-phenylindole (DAPI) were from Invitrogen (Carlsbad, CA, USA). Histopaque-1083 was from Sigma (St. Louis, MO, USA). PCR primers and SYBR Premix Ex Taq II were from Takara Bio, Inc. (Osaka, Japan). RNeasy Plus Mini kit was from Qiagen (Tokyo, Japan). Type I collagen-coated dishes were from Iwaki (Tokyo, Japan). Type I collagen-coated dishes were from Iwaki (Tokyo, Japan). Tissue-Tek OCT compound was from Sakura Finetek (Tokyo, Japan). EBM-2 medium was from Lonza (Walkersville, MD, USA). RPMI-1640 medium, antibiotic-antimycotic and fetal bovine serum (FBS) were from Life Technologies (Grand Island, NY, USA). Other chemicals were of the highest quality available.

Culture of human adenocarcinoma cells. MKN45 gastric cancer, L5174T colorectal cancer and SK-BR-3 breast cancer cells were cultured in RPMI-1640 medium supplemented with 10% FBS and 1% antibiotic-antimycotic.

ELISA assay. The culture media of human adenocarcinoma cells were collected after 72 h in culture. Contents of VEGF-A, VEGF-C, VEGF-D, epidermal growth factor (EGF) and hepatocyte growth factor (HGF) were determined by species-specific ELISA kits as previously described (15).

Bone marrow-transplanted chimera mice. All animal procedures were carried out according to a protocol approved by the Animal Care and Use Committee of Gifu University Graduate School of Medicine. GFP-positive bone marrow cells were obtained from age-matched 6 week-old C57BL/6-Tg-CAG-EGFP mice by flushing the femurs and tibias with Hank’s balanced salt solution, and mononuclear cells were isolated by density gradient centrifugation using Histopaque-1083 (16). The recipient nude mice, CanN.Cg-Foxn1nu/CrlCrlj, were lethally irradiated with 8.0 Gy, and received 6x106 donor GFP-positive bone marrow mononuclear cells intravenously (11). Bone marrow cells from 6 week-old C57BL/6J mice were used as a negative control for GFP-positive donor cells. At 4 weeks after bone marrow transplantation, mice were used for tumor implantation models. To determine the transplantation efficiency of GFP-positive bone marrow, tail peripheral blood (10 µl) or bone marrow from recipient nude mice was collected 3 weeks after tumor implantation, and GFP-positive cells spread on cover slides were analyzed by fluorescent microscopy.

Murine tumor model. At four weeks after bone marrow transplantation, 2x106 cells were subcutaneously injected into chimeric nude mice. At 3-8 weeks after tumor cell injection, mice were anesthetized, perfused with 0.1 M phosphate-buffered saline (PBS; pH 7.40) followed by 2% paraformaldehyde (PFA) in PBS and sacrificed. The tumor area was removed, fixed for 2 h with 2% PFA in PBS, and stored frozen in OCT compound (11).

Immunofluorescent staining. The cryostat sections (6 µm) of tumor tissues were immunostained with the primary antibody, rabbit anti-mouse LYVE-1 (1:100). The sections were next incubated with Alexa Fluor 594-conjugated anti-rabbit secondary antibody (1:200) and DAPI. Images were analyzed using a BIORÉVO immunofluorescence microscope (Keyence, Osaka, Japan). To evaluate lymphatic vessel density or the proportion of GFP/LYVE-1 double-positive cells, we used the inverted-gray scale images of all data (nine fields in each section), and calculated the total area positive for LYVE-1 or the area double-positive for GFP/LYVE-1 using NIH ImageJ software. To elucidate the histological structure positively stained with LYVE-1 or GFP, light hematoxylin staining was performed on the sections near the immunostained sections. Each result was obtained in at least 4 separate experiments.

Bone marrow cell culture and immunofluorescent cell staining. Bone marrow mononuclear cells were collected from C57BL/6J mice as described above. Cells plated onto type 1 collagen-coated dishes and cultured in EBM-2 medium in the absence or presence of recombinant human VEGF-A (50 ng/ml), human VEGF-C (150 ng/ml) or mouse VEGF-D (150 ng/ml). For immunofluorescent staining, cells were fixed with 2% PFA for 20 min at room temperature and were stained with rabbit anti-mouse LYVE-1 (1:100) primary antibody for 2 h at room temperature. Cells were next incubated with Alexa Fluor 594-conjugated anti-rabbit secondary antibody (1:200) at room temperature for 2 h, and also counterstained with DAPI for 2 min. Images were analyzed using a BIORÉVO immunofluorescence microscope.

Quantitative real-time RT-PCR. Total RNA was extracted from bone marrow mononuclear cells using an RNeasy Plus Mini kit and 0.5 µl of RNA was reverse transcribed to cDNA using a SuperScript VILO cDNA Synthesis kit. cDNA was amplified with SYBR Premix EX Taq II and the following primers: murine LYVE-1 (sense, 5'-CACAGCTATTGGCAACATCATC-3' and antisense, 5'-AGTAGCCCTGCTGACA-3') and mouse ACTB/β-actin. ACTB/β-actin transcripts were measured simultaneously in all reactions as internal controls. Up to 40 PCR cycles with an annealing temperature of 60°C were performed for cDNA amplification. Relative expression values were calculated from the cycle threshold (Ct) as previously described (17).

Statistical analysis. Each result was obtained in at least 5 separate experiments. All values are expressed as means ± SEM. Values were analyzed using one-way analysis of variance, and
then the significance of differences in multiple comparisons was determined using Scheffe’s multiple comparison test. P<0.01 was considered statistically significant.

Results

Human colorectal cancer LS174T cells promote lymphangiogenesis and incorporation of bone marrow-derived cells in tumor lymphatics. We developed a tumor xenograft experimental model using chimeric nude mice with GFP-positive bone marrow in order to identify the contribution of marrow-derived cells in tumor lymphangiogenesis (11). Human colorectal cancer LS174T cells were subcutaneously implanted in this chimeric nude mouse model. LS174T cells formed tumor mass (Fig. 1A) three weeks after inoculation and a tumor lymphatic-rich microenvironment as detected by LYVE-1 (Fig. 1B and C). LYVE-1-positive tumor lymphatics were located not only in peritumoral tissues but also in intratumoral tissue. Consistent with the locations of tumor lymphatics, GFP-positive cells from bone marrow were detected in peritumoral and intratumoral (Fig. 1D) tissues. Nearly 60% of LYVE-1-positive cells co-expressed GFP (Fig. 1E). These results suggest the possible involvement of bone marrow-derived cells in tumor lymphangiogenesis.

Human breast cancer SK-BR-3 cells promote lymphangiogenesis and incorporation of bone marrow-derived cells in tumor lymphatics. In the same chimeric nude mouse model, SK-BR-3 human breast cancer cells were subcutaneously injected. At 8 weeks after inoculation, SK-BR-3 human breast cancer cells formed a tumor mass (Fig. 2A) and a tumor lymphatic-rich microenvironment as detected by LYVE-1 (Fig. 2B and C).
GFP-positive cells from bone marrow were also located at peritumoral lymphatic tissues (Fig. 2D). Nearly 50% of LYVE-1-positive cells co-expressed GFP (Fig. 2E). These data also support the hypothesis that bone marrow-derived lymphatic endothelial progenitor cells are involved in the tumor lymphangiogenesis in addition to pre-existing lymphatics.

**Human malignant adenocarcinoma cells predominantly secrete VEGF-A.** In order to identify the growth factor(s) involved in the lymphangiogenesis in the peritumoral tissues, human gastric cancer MKN45, colorectal cancer LS174 and breast cancer SK-BR-3 cells were cultured in vitro and growth factors in the culture medium were measured by specific ELISA assay. Among the growth factors tested, these three cell lines predominantly produced VEGF-A at 72 h after incubation (Fig. 3). The well-characterized lymphangiogenic factors (2,3,6-8), VEGF-C and VEGF-D, were below the detectable levels in the present ELISA assay. Furthermore, secretion of other growth factors, which are implicated in lymphangiogenesis and angiogenesis (18,19), EGF and HGF, was not detected in these cells.

**VEGF-A induces differentiation of bone marrow mononuclear cells into lymphatic progenitor cells.** The present and previous (11) results suggest that VEGF-A-rich human adenocarcinomas recruit lymphatic epithelial progenitor cells from bone marrow. We further examined whether VEGF-A directly induced the differentiation of bone marrow mononuclear cells into lymphatic endothelial progenitor cells. First, bone marrow mononuclear cells were cultured in the absence or presence of VEGF family proteins and the relative expression of LYVE-1, a specific lymphatic endothelial marker, was analyzed. VEGF-A significantly increased LYVE-1 mRNA in bone marrow cells at 6 h after administration (Fig. 4). At the same time, VEGF-C and VEGF-D tended to increase LYVE-1 mRNA, yet the increase was not statistically significant. To further confirm VEGF-A-dependent differentiation of bone marrow mononuclear cells into lymphatic endothelial lineage cells, bone marrow cells were incubated with VEGF-A and immunostained with antibody against LYVE-1. In the control culture without VEGF family proteins, most of the attached cells were positive for CD34, a marker of hematopoietic and vascular endothelial progenitor cells (data not shown), but negative for LYVE-1 (Fig. 5A). The well-characterized lymphangiogenic factors, VEGF-C (Fig. 5B) and VEGF-D (Fig. 5C), stimulated the expression of LYVE-1 in bone marrow mononuclear cells in this analysis system after incubation for 40 h; 50-60% cells were positive for LYVE-1. VEGF-A also clearly induced the increase of LYVE-1 positive bone marrow mononuclear cells (Fig. 5D). Nearly 60% of cells became positive for LYVE-1 at 40 h after incubation. These results suggest the differentiation of bone marrow mononuclear cells into lymphatic endothelial lineage cells in response to VEGF-A.

**Discussion**

The formation of a lymphatic vascular system is a dynamic process during embryogenesis. In embryos, the blood circulatory system is first to evolve, followed by specification of lymphatic endothelial progenitor cells differentiated from blood vascular endothelial cells and budding of these cells from the cardinal vein (20). Under normal physiological postnatal conditions, however, the formation of new lymphatic vessels...
scarce occurs. In adults, lymphangiogenesis only takes place during certain pathological conditions such as inflammation, tissue repair and tumor growth. Postnatal lymphatic vessel formations have been assumed to occur mainly by hyperplasia of lymphatic vessels themselves, or sprouting from pre-existing lymphatics. The relative contribution to the formation of new vessels from circulating endothelial progenitor cells is not yet clearly understood. Integration of bone marrow-derived cells into tumor lymphatics was initially denied in a mouse xenograft model with Lewis lung carcinoma or B16-F1 melanoma cells (21). In contrast, the involvement of bone marrow-derived cells in lymphatic vessel formation has been suggested in human kidney transplants (22) and mouse corneal lymphangiogenesis model (23). Moreover, the role of bone marrow progenitor cells in tumor lymphangiogenesis has recently been reported (23-25). We have previously shown that bone marrow-derived cells are involved in the formation of tumor lymphatics in a mouse xenograft model with human gastric cancer MKN45 cells (11). In the present study, we showed that in the same experimental model with chimeric nude mice bearing GFP-positive bone marrow, human colorectal cancer LS174T and breast cancer SK-BR-3 cells also recruited bone marrow-derived cells in the formation of tumor lymphatics. These results indicate that bone marrow-derived lymphatic endothelial progenitor cells participate in the human adenocarcinoma-induced lymphangiogenesis in addition to pre-existing lymphatics.

Several factors with prolymphangiogenic activity have been identified to date (2,3,20). These include VEGF-A, VEGF-C, VEGF-D and HGF. Attention has been focused on the role of VEGF-C and VEGF-D in recent years (2,3). Using mouse models, overexpression of VEGF-C or VEGF-D has been shown to increase lymphatic vessel density, vessel diameter and lymph node and organ metastasis of many types of cancer (6-8). A role for VEGF-A in tumor-mediated lymphangiogenesis and metastasis has also been reported (9,10). In the present study, three malignant adenocarcinomas examined predominantly secreted VEGF-A with minimal productions of VEGF-C and VEGF-D. Various types of human cancer cells extensively secrete VEGF-A and this ability is often associated with poor prognosis (26-29). VEGF-A is a key factor of new blood vessel formation (angiogenesis) to support tumor growth and metastatic dissemination (26,27). Moreover, recent reports have demonstrated the immunosuppressive effects of VEGF-A by induction of regulatory T cells (29,30) and by reduction of cytotoxic T cell activity (31).

Despite its initial recognition as a master regulatory molecule in angiogenesis (26,27), previous studies indicated that VEGF-A also plays a role in lymphangiogenesis in tumor (8,9), inflammation (33,34) and wound healing (35) models. VEGF-A may indirectly induce lymphangiogenesis via recruitment of VEGF-C/D producing macrophages (32). The role of VEGF-A appears to vary depending on the tissue microenvironment (9,10,34,35). The data obtained in the present study show that the expression of a lymphatic endothelial-specific marker, LYVE-1, increased in in vitro culture of mouse bone marrow mononuclear cells in the presence of VEGF-A as assessed by immunostaining as well as real-time PCR. These results indicate that VEGF-A is able to directly promote differentiation of bone marrow mononuclear cells into lymphatic endothelial lineage cells.

In summary, the present study indicated that human malignant adenocarcinoma cells, which extensively secrete VEGF-A, promote tumor lymphangiogenesis in part via recruitment and incorporation of bone marrow-derived lymphatic endothelial progenitor cells into tumor lymphatics. The mechanism
involves direct effect of VEGF-A on the differentiation of bone marrow mononuclear cells into lymphatic lineage cells.

Acknowledgements

This study was supported in part by a NaSNeLC research grant from Gifu University Graduate School of Medicine. The authors thank Ryoko Hayashi for her technical assistance.

References